Title : Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.

Pub. Date : 2022 Jan

PMID : 35242683






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we assessed the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel in women with human epidermal growth factor receptor 2-positive early or locally advanced BC. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Conclusions: In women with human epidermal growth factor receptor 2-positive early or locally advanced BC, neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel effectively promoted total pCR rate with an acceptable safety profile (ClinicalTrials.gov, NCT04152057). Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens